Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Economic information and modeling report

Modeling overview

12 evidence topics · 11 sources

Summary

No budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec was found, and CG Oncology has announced no price. Its Form 10-K states that the “pricing of existing drugs may limit the amount we will be able to charge for our products”. Published U.S. economic evaluations in BCG-unresponsive high-risk NMIBC address the approved comparators. A Ferring-funded budget impact model of nadofaragene firadenovec estimated a budget impact of $0.0010 to $0.0084 per member per month over 3 years in a plan of one million members for CIS ± Ta/T1 disease, and $0.0064 to $0.0548 when papillary-only disease was included; the authors note that cretostimogene was “under investigation in ongoing trials for similar indications” and was not modeled. A 5-year Medicare Markov model found gemcitabine/docetaxel the most cost-effective option for a patient willing to try one line of therapy or proceed directly to radical cystectomy, radical cystectomy for a patient open to two lines of therapy or upfront radical cystectomy, and pembrolizumab for a patient willing to try up to 2 lines of FDA-approved therapy before radical cystectomy. A Johnson & Johnson-funded 15-month cost-per-responder model estimated that 43.5% of patients treated with TAR-200 achieved and sustained a complete response for at least 12 months, against 18.8% to 26.8% for pembrolizumab, nadofaragene firadenovec, and nogapendekin alfa inbakicept plus BCG without reinduction, and 10.1% for valrubicin. The 2020 ICER review estimated $151,000 per QALY gained for nadofaragene firadenovec and $114,000 for pembrolizumab against a hypothetical comparator with a 0% complete response rate, and a health-benefit price benchmark of $158,600 to $262,000 per year for nadofaragene firadenovec. Two other models found pembrolizumab not cost-effective at its price at the time, one estimating that a 5.4% price reduction would make it cost-effective, and a further analysis found nadofaragene firadenovec cost-effective against radical cystectomy at $10,014 per QALY at a willingness-to-pay threshold of $100,000. ImmunityBio reported preliminary results of a health economic analysis, based on complete response rates from an indirect treatment comparison, in which nogapendekin alfa inbakicept plus BCG had a lower cost per sustained complete responder than TAR-200.

Budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec

No evidence found.

ICER review of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab